690results about "Sexual disorder" patented technology

The invention relates to a traditional Chinese medicine composition with functions of tonifying qi and nourishing blood for livestock. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-30 parts of astragalus membranaceus, 10-40 parts of spina gleditsiae, 10-20 parts of angelica sinensis, 10-20 parts of codonopsis pilosula, 10-30 parts of uniflower swisscentaury root, 10-30 parts of ligusticum wallichii, 10-20 parts of cowherb seed, 10-20 parts of fruit of liquidambar formosana hance and 1-10 parts of iron sucrose. The traditional Chinese medicine composition is scientific and reasonable in component, free of toxic and side effects and medicine residue, convenient to take and low in cost, has the functions of tonifying qi and nourishing blood, stimulating the menstrual flow and prompting lactation, and is capable of effectively treating diseases of postpartum hypogalactia, breast milk stoppage and the like which are normal in livestock.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

This invention relates to the field of nursing gel technology, and discloses a moisturizing nursing gel and its preparation method. The nursing gel is prepared from deionized water, poloxamer 407 powder, β-glucan, an antibacterial composite particle dispersion, and an aqueous lactic acid solution. The antibacterial composite particle dispersion is prepared from chitosan, an aqueous acetic acid solution, an antibacterial moisturizer, a modified sodium alginate solution, and deionized water. The modified sodium alginate solution is prepared from an aqueous sodium alginate solution, an aqueous sodium hydroxide solution, dopamine hydrochloride, 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride, and deionized water. The antibacterial moisturizer is prepared from sodium hyaluronate, fructooligosaccharides, deionized water, polyhexamethylene biguanide hydrochloride, sodium pyrrolidone carboxylate, triethanolamine, sodium lactate, and an aqueous solution of 1,4-butanediol diglycidyl ether. This invention exhibits good antibacterial and moisturizing properties.

The present invention addresses the problem of specifically clarifying the effects on a fertilized egg when 5-ALA is administered to a human female suffering from infertility, and constructing a more effective means for treating infertility through the suppression of chromosomal abnormalities. It has been confirmed that, when 5-ALA is ingested in combination with a drug therapy that is generally performed in the treatment of female infertility, the rate of chromosome aneuploidy in a fertilized egg or the like is significantly reduced, and the qualitative improvement of an embryo through improvement of the stability of the chromosomes is expected.

The present invention discloses an antitumor pharmaceutical composition based on immune checkpoint blockade and its application, which comprises paroxetine hydrochloride and a T cell enhancer, which is at least one of vitamin E and thymosin. Through a series of in vitro and in vivo experiments, the present invention has first discovered that cannabidiol and paroxetine hydrochloride can effectively reduce the expression of PD-L1 on the surface of tumor cells, block the PD-1 / PD-L1 signaling pathway, and enhance the tumor cell killing effect of T cells. Based on this, the addition of a T cell enhancer can further increase the number and activity of T cells, significantly enhancing the killing ability of T cells after immunosuppression is released, thereby significantly enhancing the antitumor effect of the drug. The components of the pharmaceutical composition of the present invention, cannabidiol, paroxetine hydrochloride, vitamin E, and thymosin, exert a synergistic effect, improving the antitumor effect.

The disclosure provides new transmucosal and subcutaneous pharmaceutical compositions comprising 1-(4-fluoro-phenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or 1-(4-fluorophenyl)-4-((6bR,10aS)-2,2-d2-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one or comprising -(4-fluoro-phenyl)-4-((6bR,10aS)-1,1,2,2-d4-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)-butan-1-one, in free base, co-crystal or salt form, together with methods of making and using them.

The present disclosure relates to compositions and methods useful for the treatment and / or prevention of obesity and obesity-related diseases in a subject in need thereof. In various embodiments, the present disclosure relates to uses of compounds that are inhibitors of sphingosine kinase-2 (SphK2), dihydroceramide desaturase (DES1) and / or hexosylceramide synthase (GCS), such as opaganib, in the treatment and / or prevention of obesity and obesity-related diseases.

The present disclosure provides a HER2 binder comprising a VHH domain that specifically binds to HER2. Also provided are nucleic acids encoding the protein, vectors and host cells comprising the nucleic acids, and methods of manufacturing and using the HER2 binder. The present disclosure also provides a HER2 binder conjugate in which the protein is conjugated to a detectable label, and a HER2-binding targeted radiotherapy agent for therapeutic and / or diagnostic purposes. Also provided are methods of using the HER2 binder for detecting, monitoring and / or treating diseases and conditions such as cancer.

A method of treating male hypogonadism in a subject in need thereof includes administering to the subject testicular organoids generated from isolated male progenitor cells. The method can be used to slow or halt the progression of age-related diseases, and increase healthspan and longevity, in hypogonadal males. The method can be used with subjects that have not or are not receiving testosterone replacement therapy. The method does not require that the subject is pre-treated with CG. The testicular organoid includes cells expressing GFRA1, VEGF, VEGFR2, PDGF-Rα, Cyp11A1, 3β-HSD, 17β-HSD, LHCGR, α-SMA, CD11b, MHC CII, CD64, CD95, Sox9, AR, inhibin β-B, and FSHR.

The application discloses an active oxygen response type bacteriostatic and repair promoting hydrogel and a preparation method and application thereof, the hydrogel is formed by disulfide bond cross-linked hydrogel in response to active oxygen free radicals in the vagina of vaginitis patients through thiol modified hyaluronic acid (HASH), and can enhance in-vivo retention by thiol and vaginal tissue interaction. Cationic surfactant such as didecyldimethylammonium chloride (DDAC) as the bacteriostatic component of the hydrogel, efficiently killing pathogenic bacteria while having good biocompatibility, and is not prone to cause bacterial drug resistance. As a natural immune regulator, beta-glucan regulates the vaginal microenvironment, promotes the polarization of macrophages into anti-inflammatory M2 type and promotes cell migration, etc., to promote the repair of the vaginal immune barrier, regulate the vaginal flora, and reduce the probability of vaginitis recurrence. The HASH hydrogel provides an efficient, convenient and highly transformative potential strategy to provide more choices for the treatment of vaginitis.

The present application relates to the field of biological medicine and modernization of traditional Chinese medicine, and particularly relates to a therapeutic target, an inhibitor and a traditional Chinese medicine composition for treating ovarian hypofunction caused by oxidative stress and application thereof. The present application first determines SRC tyrosine kinase as a key drug target for preventing and treating the disease. The application of the SRC tyrosine kinase inhibitor (such as secaitinib) in preparing related drugs is provided, which can alleviate the damage of ovarian granulosa cells by inhibiting the SRC activity, down-regulating the expression of antioxidant enzyme related genes and reducing the level of active oxygen. Meanwhile, the present application provides a traditional Chinese medicine composition composed of mulberry, kudzu root, tuckahoe and medlar. The composition can improve the hormone level, enhance the antioxidant capacity, improve the ovarian function and fertility by inhibiting the SRC tyrosine kinase activity and the SRC-RAF1-MEK-ERK signal pathway. The present application provides a new solution for the targeted treatment of ovarian hypofunction and the modernization of traditional Chinese medicine.

The present invention relates to a combination of a specific binding molecule that binds to human ANXA1 and a second active agent for use in the treatment of cancer. The second active agent includes thymidylate synthase inhibitors, nucleobase analogs, checkpoint inhibitors, proteasome inhibitors, taxanes, platinum-based chemotherapy agents, and nucleoside analogs. Suitable cancers for treatment include pancreatic cancer, colon cancer, breast cancer, lung cancer, myeloma, and mantle cell lymphoma. Also provided are related kits, products, and uses.

The application discloses a recombinant oncolytic virus targeting CD317 gene and application thereof in anti-tumor, and belongs to the technical field of tumor treatment. The recombinant oncolytic virus comprises a CD317 inhibitor and an oncolytic virus, and is formed by integrating the CD317 inhibitor into the oncolytic virus genome. The CD317 inhibitor is a substance capable of inhibiting CD317 gene expression or targeting degradation of CD317 protein function, and is selected from shRNA or siRNA targeting CD317. The application develops the oncolytic virus targeting knockdown of CD317 expression, inhibits tumor cell proliferation by reducing CD317 expression of tumor cells, reduces PD-L1 expression so as to break the immune escape mechanism, simultaneously enhances the killing sensitivity of tumor cells to CD8+ T cells, forms a synergistic effect with the oncolysis of the oncolytic virus, and the recombinant oncolytic virus has stronger in-vivo anti-tumor activity, thereby providing a new potential scheme for CD317-driven tumor treatment.

The application belongs to the technical field of biological medicine, and particularly relates to application of an expression inhibitor of miR-8072 in preparation of an ER-positive breast cancer treatment drug. It is found for the first time that overexpression of miR-8072 causes estrogen receptor-positive breast cancer to be resistant to tamoxifen. Targeted inhibition of miR-8072 expression for treatment is an effective way to resist tamoxifen resistance in estrogen receptor-positive breast cancer.

The present application belongs to the technical field of daily chemical preparation, and particularly relates to a gynecological gel for inhibiting bacteria, regulating microecological balance and tightening vagina and a preparation method thereof. The gynecological gel comprises the following raw materials in mass fractions: 0.5-1 parts of carbomer, 0.04-0.09 parts of sodium hydroxide, 1-3 parts of collagen, 0.01-0.06 parts of sodium hyaluronate, 0.5-1.5 parts of isomaltooligosaccharide, 2-5 parts of propylene glycol, 0.05-0.3 parts of hydroxybenzoic acid methyl ester, 0.02-0.15 parts of hydroxyphenyl ethyl ester, 0.1-1.5 parts of hydrogenated lecithin, 1-6 parts of 1,3-butanediol, 3-5 parts of glycerol, 0.5-1 part of xanthan gum and 70-90 parts of water. The present application uses buckwheat filtrate to prepare collagen, and the active ingredients in the buckwheat filtrate can penetrate the cell membrane of pathogenic bacteria to play an antibacterial role; the collagen can repair the vaginal mucosa barrier and reduce the adhesion and invasion of pathogenic bacteria; therefore, after being compounded with the raw materials such as carbomer, sodium hydroxide, sodium hyaluronate, isomaltooligosaccharide and propylene glycol, the multiple components can synergistically promote the synthesis and repair of collagen fibers and improve the elasticity of tissues.

There are disclosed psychedelic and entactogen compounds, the use of such compounds in the treatment of diseases associated with a serotonin 5-HT2 receptor, pharmaceutical compositions such as tablet compositions and kits containing the compounds, methods of delivering the compounds in a mist via inhalation, and methods of treating diseases or disorders associated with a serotonin 5-HT2 receptor, such as central nervous system (CNS) disorders or psychological disorders with the compounds of the invention.

This invention relates to the field of traditional Chinese medicine technology, and discloses a traditional Chinese medicine composition for treating male infertility and its preparation method, which is made from the following raw materials in parts by weight: Astragalus membranaceus 12-18 parts, Rehmannia glutinosa 12-18 parts, Atractylodes macrocephala stir-fried with wheat bran 10-13 parts, Cuscuta chinensis 10-13 parts, Lycium barbarum 10-13 parts, Cervi cornu colla 8-10 parts, Cornus officinalis 8-10 parts, Angelica sinensis 5-7 parts, Schisandra chinensis 2.5-4 parts, and Glycyrrhiza uralensis (processed with honey) 2.5-4 parts. This invention uses Astragalus membranaceus instead of ginseng and deer antler glue instead of Aconitum carmichaelii and cinnamon. It addresses the deficiency of both the spleen and kidneys with gentle nourishment, resulting in fewer side effects. The entire formula is mild and gentle, avoiding strong pungent and hot ingredients and greasy ingredients that may harm the stomach. It is suitable for modern constitutions and long-term conditioning. The preparation uses a process of extraction and coagulation, which involves decocting the herbal medicines in water and simmering the deer antler glue in rice wine at low temperature. This process fully extracts the water-soluble active ingredients while retaining the active substances in the deer antler glue, ensuring the stable coexistence of the active ingredients and the uniformity, stability, and bioavailability of the preparation.

The present invention relates to in vitro methods for production of testis cells (e.g., Sertoli and / or Leydig cells) and related organoids. The testis cells and testis like organoids may be used for therapeutic purposes including facilitation of the production of spermatogonia from pro-spermatogonia stem cells.

The application belongs to the technical field of microbial fermentation, and particularly relates to a fermented lactobacillus mucioparius FJ701 and application of the fermented lactobacillus mucioparius FJ701 in preparation of high-biological-activity angelica fermentation product. The angelica fermentation product prepared by fermentation of the fermented lactobacillus mucioparius FJ701 has high content of dihydroferulic acid, butenyl phthalide, polyphenol and flavone, and in vitro simulation digestion experiments show that the bioavailability of dihydroferulic acid, butenyl phthalide and polyphenol is significantly improved.

The application discloses an ANAPC11 inhibitor for treating triple-negative breast cancer. Specifically, the siRNA of the application can effectively knock out ANAPC11, treat triple-negative breast cancer, and also increase the sensitivity of tumors to ferroptosis. The siRNA targeting ANAPC11 of the application is combined with a ferroptosis inducer or a chemotherapy drug, so that the killing effect on tumor cells can be effectively improved, especially for tumors with ferroptosis drug resistance.

The application relates to the field of triple-negative breast cancer treatment and relates to synthesis of an acid-responsive amphiphilic liposome and application of the acid-responsive amphiphilic liposome in tumor treatment. A chemotherapeutic drug, a phospholipid, cholesterol and a polyethylene glycolized lipid are dissolved in an organic solvent chloroform, vacuum rotary evaporation is carried out under certain temperature and rotation rate, a water phase is added for hydration, a polypeptide nanogold cluster solution is added for ultrasonic treatment, then crushing, molecular sieve screening, dialysis and ultrafiltration are carried out to obtain a pH-sensitive liposome; in the preparation process, the phospholipid spontaneously forms a kind of biological membrane-like phospholipid bilayer membrane vesicle in water, and the chemotherapeutic drug and the nanogold cluster are wrapped in the vesicle. The pH-sensitive liposome can target the triple-negative breast cancer tumor site through pH response, can improve the solubility of the chemotherapeutic drug, can realize high-efficiency treatment effect of the drug at a low dose, can obviously reduce the toxic side effect of the chemotherapeutic drug, and can realize effective treatment of the triple-negative breast cancer.

The application discloses application of PGD2 in promoting rumen development of young ruminants, and application of PGD2 in young ruminants promotes proliferation and differentiation of rumen wall cells, and further promotes rumen development and improves the digestive and absorptive capacity of the rumen. 2+ It is found that PGD2 can promote rumen development by activating Ca signal pathways, promoting expression of CAMK2A protein, promoting cell cycle progression, promoting rumen development, and ensuring animal health. Therefore, PGD2 can be used for preparing a medicine for promoting rumen development of young ruminants.

The present application relates to the field of pharmaceutical chemistry, and relates to a thienopyrimidine derivative and application thereof, in particular to a series of thienopyrimidine derivatives, which are compounds shown in formula (I), or pharmaceutically acceptable salts thereof, medical uses of the compounds and pharmaceutical compositions containing the compounds in the preparation of drugs for preventing or treating cervical cancer. In vitro experiments show that the compounds exhibit significant dose-dependent proliferation inhibition activity on cervical cancer cell lines (SiHa, Hela, Caski, Me-180 cells), and the IC 50 values reach micromolar level. The present application discloses new medical uses of the compounds, and provides new treatment options and candidate drugs for clinically refractory cervical cancer.

Provided in the present invention is use of a combination of FGF-2 and Flavokawain C in the preparation of a drug for treating uterine adhesions. In the present invention, a gel prepared using FGF-2 and Flavokawain C has a therapeutic effect on uterine adhesions, and can repair the morphology and function of the damaged uterus.

The present application belongs to the technical field of traditional Chinese medicine composition, and relates to a traditional Chinese medicine transdermal external preparation for treating vulvar hypopigmentation disease. The preparation is a paste prepared by mixing traditional Chinese medicine powder and horse oil. The traditional Chinese medicine powder is composed of the following raw materials by weight: Xuchangqing 10-12, Pugongying 10-15, Difusiduo 12-15, Tuzifuding 12-15, Baiji 10-15, Huzhang 9-12, Quansie 6-10, Diyu 10-12, Xuezhi 10-12, Danggui 6-10, Rushang 6-10, Miedu 6-10, Bingpian 1-3. The traditional Chinese medicine transdermal external preparation has definite and significant effects on vulvar hypopigmentation disease, especially in relieving intractable pruritus, promoting pigment recovery and improving skin sclerosis / atrophy. The traditional Chinese medicine transdermal external preparation has high safety, few adverse reactions and low recurrence rate.

Disclosed herein are novel bifunctional compounds formed by conjugating an EGFR inhibitor moiety with an E3 ligase ligand moiety, methods for preparing the same, and uses thereof.

The present application provides a kind of probiotic compound and its application in preventing and repairing gynecological reproductive tract mucosa damage.The compound is composed of core probiotic, mucosa repair auxiliary component and sustained-release carrier, which are collectively encapsulated in the sustained-release carrier to form drug-loaded microspheres, with total viable count ≥1×10 10 CFU / g; the mucosa repair auxiliary component is a specific ratio combination of snail mucus active peptide, L-arginine and phytosterol; the sustained-release carrier is γ-ray modified chitosan and sodium alginate composite microspheres, which are matched with prebiotics for directional synergism, realize bacteriostasis, mucosa repair and microecological regulation functions through multi-component synergy, solve the problem of easy inactivation and weak repair ability of traditional products, provide a safe and effective new solution for gynecological health, and can be prepared into various dosage forms such as suppositories and gels, with wide application prospect.

The present invention relates to pharmaceutical compositions containing a solid dispersion of N- [2,4-B is( 1, 1 -dimethy lethyl)-5 -hydroxypheny 1] - 1,4-dihydro-4-oxoquinoline-3 - carboxamide including formulations of the solid dispersions into powders, granules and mini- tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.